| Literature DB >> 28855818 |
P B Benil1, R Lekshmi2, N Viswanathan3, E Jollykutty3, R Rajakrishnan4, J Thomas4, A H Alfarhan4.
Abstract
Coronary Artery Disease (CAD) is a major killer disease throughout the world. Dyslipidemia is a major contributor to the risk of CAD. Several dietary articles traditionally used in India and other South Asian countries reduced dyslipidemia. The present study was undertaken to evaluate the combined effect of Mung bean (Vigna radiata) and Elephant foot yam (Amorphophallus paeoniifolius) on serum lipids and atherogenic indices in albino rats and to compare it with a standard drug Cholestyramine. Thirty healthy albino rats of both sexes (150-200 g) were randomized to 5 groups of 6 animals each. The grouping were done based on the following criteria: Group I: Normal Control Group, Group II: (Standard Group): Cholestyramine resin 5 mg/kg bw, Group III: (Half Dose Group): Drug powder at 540 mg/kg bw, Group IV: (Effective Dose Group): Drug powder at 1080 mg/kg bw, and Group V: (Double Dose Group): Drug powder at 2160 mg/kg bw. Lipid profile was estimated at the beginning and after 30 days of treatment. The Effective and Double doses of the drug reduced Total cholesterol along with levels of Triglycerides, Low density lipoprotein and Very low density lipoprotein levels significantly (p < 0.01) along with a significant (p < 0.01) increase in high density lipoproteins (HDL) in rats. There was also significant (p < 0.01) improvement in atherogenic indices like Castelli Risk Index I, Non HDL C/HDL, Castelli risk Index II, TG/HDL, Atherogenic coefficient and Atherogenic Index of Plasma. The combination of powdered sprouted mung bean and yam powder have excellent lipid lowering potential.Entities:
Keywords: Atherogenic index; Cholestyramine; Dyslipidemia; Lipid profile
Year: 2017 PMID: 28855818 PMCID: PMC5562459 DOI: 10.1016/j.sjbs.2017.03.003
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.219
Effect of drug on serum lipid levels.
| Group | Total cholesterol | Triglycerides | Hdl | Ldl | Vldl |
|---|---|---|---|---|---|
| Normal | 141.0 ± 5.13 | 93.66 ± 2.71 | 30.83 ± 2.7 | 91.66 ± 5.7 | 18.5 ± 0.56 |
| Standard | 96.8 ± 3.6 | 80.5 ± 3.91 | 32.0 ± 3.57 | 48.83 ± 3.51 | 16.0 ± 0.68 |
| Effective dose | 103.0 ± 2.13 | 74.33 ± 4.68 | 49.3 ± 3.35 | 38.83 ± 3.5 | 14.83 ± 0.91 |
| Half dose | 115.83 ± 5.8 | 80.83 ± 5.12 | 38.3 ± 2.21 | 58.66 ± 7.3 | 16.2 ± 1.07 |
| Double dose | 98.50 ± 2.06 | 78.33 ± 6.06 | 39.0 ± 1.74 | 55.33 ± 9.5 | 15.66 ± 1.20 |
| F Ratio | 8.25 | 4.177 | 4.936 | 5.857 | 4.04 |
| Df | 4, 25 | 4, 25 | 4, 25 | 4, 25 | 4, 25 |
Values are expressed as Mean ± SEM, (n = 6), serum lipid levels are expressed in mg/dl. One-way ANOVA followed by Dunnet’s Multiple comparison post hoc test have been performed with the normal group and Standard group.
p < 0.05.
p < 0.01.
p < 0.001.
p > 0.05.
Atherogenic index and percentage protection in different groups.
| Cri i | Non-hdl c/hdl | Cri ii | Tg/hdl | Plasma ai | % protection | |
|---|---|---|---|---|---|---|
| Normal | 4.6 ± 0.15 | 3.6 ± 0.22 | 3.0 ± 0.37 | 3.0 ± 0.34 | 0.18 ± 0.04 | 0 |
| Standard | 3.0 ± 0.18 | 2.0 ± 0.18 | 1.5 ± 0.27 | 2.5 ± 0.1 | 0.24 ± 0.01 | 39.4 |
| Effective dose | 2.1 ± 0.07 | 1.1 ± 0.02 | 0.8 ± 0.13 | 1.5 ± 0.14 | 0.29 ± 0.01 | 51.2 |
| Half dose | 3.0 ± 0.19 | 2.0 ± 0.11 | 1.5 ± 0.09 | 2.1 ± 0.29 | 0.24 ± 0.02 | 45.8 |
| Double dose | 2.5 ± 0.08 | 1.5 ± 0.27 | 1.4 ± 0.12 | 2.0 ± 0.25 | 0.26 ± 0.01 | 33.7 |
| F ratio | 42.01 | 25.88 | 12.77 | 5.61 | 3.48 | – |
| Df | 4, 25 | 4, 25 | 4, 25 | 4, 25 | 4, 25 | – |
Values are expressed as Mean ± SEM, (n = 6). One-way ANOVA followed by Dunnet’s Multiple comparison post hoc test have been performed with the normal group and Standard group.
p < 0.05.
p < 0.01.
p < 0.001.
p > 0.05.
Fig. 1Effect of the drug on serum lipid levels.
Fig. 2Percentage protection of the drug in various groups.
Fig. 3Atherogenic indices in various groups after drug treatment.